Global genomic diversity of HPV6 and HPV11 based on 737 HPV6/11 isolates and 268 complete genome sequences.

MATEJA M JELEN; ZIGUI CHEN; BOSTJAN J. KOCJAN; FELICITY J. BURT; PAUL K. S. CHAN; DIEGO CHOUHY; CATHARINA E. COMBRINCK; FRANÇOIS COUTLÉE; CHRISTINE ESTRADE; ALEX FERENCZY; ALISON FIANDER; EDUARDO L. FRANCO; SUZANNE M. GARLAND; ADRIANA A. GIRI; JOAQUÍN VÍCTOR GONZÁLEZ; ARNDT GRÖNING; KERSTIN HEIDRICH; SAM HIBBITTS; LEA HOSNJAK; TOMMY N. M. LUK; KARINA MARINIC; TOSHIHIKO MATSUKURA; ANNA NEUMANN; ANJA OSTRBENK; MARIA ALEJANDRA PICCONI; HARRIET RICHARDSON; MARTIN SAGADIN; ROLAND SAHLI; RIAZ Y. SEEDAT; KATJA SEME; ALBERTO SEVERINI; JESSICA L. SINCHI; JANA SMAHELOVA; SEPEHR N. TABRIZI; RUTH TACHEZY; SARAH TOHME; VIRGILIJUS ULOZA; ASTRA VITKAUSKIENE; YONG WEE WONG; SNJEZANA ZIDOVEC LEPEJ; ROBERT D. BURK; MARIO POLJAK

Trieste

Congreso; DNA Tumour Virus Meeting; 2015

International Centre for Genetic Engineering and Biotecnology (ICGEB)

INTRODUCTION: Human papillomaviruses (HPVs) HPV6 and HPV11 are the two medically most importan low-risk HPV types, etiologically associated with the majority of anogenital warts and laryngeal papillomas worldwide. HPV6 and HPV11 have been included in two highly effective, quadrivalent and nonavalent HPV vaccines. In our study, we extensively sudied the global genomic diversity of HPV6/11 and phylogenetically evaluated relationships among the most variable HPV6/11 complete genome (CG) variants, circulating worldwide.METHODS: In total, 530 HPV6 and 207 HPV11 isolates from the anogenital and head and neck anatomical regions were obtained from fifteen countries, covering six continents. HPV6/11 isolates were analysed in concatenated genomic regions: E5a-E5b-L1-LCR (approximately 2,700 bp) and the most variable isolates were sequenced throughout the CG (approximately 8,000 bp). Maximum likelihood (RAxML) phylogenetic trees were constructed, HPV6/11 (sub)lineage-specific SNPs were identified and geographical and clinical associations among HPV6/11 genomic variants were statistically evaluated.RESULTS: In total, 130 HPV6 and 30 HPV11 CGs were obtained. Pairwise differences of 190 HPV6 CGs (130 from our study, 60 from GenBank) and 78 HPV11 CGs (30 from our study, 48 from GenBank) were 1.6% and1.4%, respectively. Global phylogenetic trees revealed two lineages, A and B, and five sublineages: B1-B5 for HPV6 and two lineages, A and B, and four sublineages: A1-A4 for HPV11. HPV6 sublineages B4 and B5 and HPV11 lineage B, sublineages A3 and A4 were discovered for the first time in our study. Among HPV6 variants lineage B prevailed globally, lineage A in Asia and sublineage B3 in Africa, Norh and South America. HPV6 sublienages B1 and B3 were associated with anogenital infections and B3 showed higher odds for infection in females.Among HPV11 variantes sublineage A2 prevailed worldwide, followed by sublineage A1. The newly assigned HPV11 lineage/sublineage B, A3 and A4 were found in African, North America/Australian and European HPV11 isoltes, respectively. Clinical associations among HPV11 sublineages are currently being statistically evaluated.CONCLUSION: This study represents the first extensive work on globally circulating HPV6/11 genomic variants in the pre-vaccination era. Preliminary results suggest the existence of novel HPV6 lineage/sbulineages, exhibiting some degree of ethnogeographic, gender and/or disease predilection in their distribution.